Alfonso Arrazate

440 total citations
6 papers, 67 citations indexed

About

Alfonso Arrazate is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alfonso Arrazate has authored 6 papers receiving a total of 67 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alfonso Arrazate's work include PI3K/AKT/mTOR signaling in cancer (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and CAR-T cell therapy research (2 papers). Alfonso Arrazate is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and CAR-T cell therapy research (2 papers). Alfonso Arrazate collaborates with scholars based in United States, Italy and Singapore. Alfonso Arrazate's co-authors include James Ziai, Kevin B. Walsh, Melissa R. Junttila, Teemu T. Junttila, Ji Li, Ryan Ybarra, Judy Mak, Patrícia de Almeida, Aurélie Hérault and Klára Tótpál and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and EMBO Reports.

In The Last Decade

Alfonso Arrazate

6 papers receiving 61 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfonso Arrazate United States	4	36	25	21	18	10	6	67
Carlos Hickey United States	5	59 1.6×	25 1.0×	41 2.0×	36 2.0×	10 1.0×	6	105
Pei Rong Evelyn Lee United States	3	42 1.2×	10 0.4×	26 1.2×	39 2.2×	12 1.2×	3	91
Deanna Mohn United States	4	25 0.7×	76 3.0×	10 0.5×	54 3.0×	14 1.4×	6	127
Layton Woolford United States	3	58 1.6×	36 1.4×	38 1.8×	16 0.9×	27 2.7×	8	104
Adrien Procureur France	4	44 1.2×	21 0.8×	6 0.3×	17 0.9×	16 1.6×	6	68
Drew Dudgeon United States	4	41 1.1×	27 1.1×	41 2.0×	23 1.3×	8 0.8×	6	81
Fernando Vidal‐Vanaclocha Spain	5	24 0.7×	14 0.6×	9 0.4×	31 1.7×	6 0.6×	8	67
Joana L. Mora United States	2	47 1.3×	11 0.4×	9 0.4×	47 2.6×	36 3.6×	3	95
Reynald Lescarbeau United States	3	24 0.7×	9 0.4×	5 0.2×	20 1.1×	14 1.4×	6	68
Alexander M. Leipold Germany	4	38 1.1×	13 0.5×	11 0.5×	14 0.8×	10 1.0×	7	63

Countries citing papers authored by Alfonso Arrazate

Since Specialization

Citations

This map shows the geographic impact of Alfonso Arrazate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso Arrazate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso Arrazate more than expected).

Fields of papers citing papers by Alfonso Arrazate

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfonso Arrazate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso Arrazate. The network helps show where Alfonso Arrazate may publish in the future.

Co-authorship network of co-authors of Alfonso Arrazate

This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso Arrazate. A scholar is included among the top collaborators of Alfonso Arrazate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso Arrazate. Alfonso Arrazate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Himmels, Patricia, Alfonso Arrazate, Robyn Clark, et al.. (2023). T cell‐dependent bispecific antibodies alter organ‐specific endothelial cell–T cell interaction. EMBO Reports. 24(3). e55532–e55532. 6 indexed citations

2.

Edgar, Kyle A., Rebecca Hong, Kyung Song, et al.. (2020). Abstract P3-11-23: GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models. Cancer Research. 80(4_Supplement). P3–11. 2 indexed citations

3.

Li, Ji, Ryan Ybarra, Judy Mak, et al.. (2018). IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody. Clinical Cancer Research. 24(24). 6447–6458. 34 indexed citations

4.

Edgar, Kyle A., Emily J. Hanan, Steven T. Staben, et al.. (2017). Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development. Cancer Research. 77(13_Supplement). 156–156. 11 indexed citations

5.

Chiang, Po‐Chang, Stephen E. Gould, Michelle Nannini, et al.. (2014). Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity. Nanoscale Research Letters. 9(1). 156–156. 12 indexed citations

6.

Nannini, Michelle, Rebecca Hong, Brian B. Lee, et al.. (2012). Abstract 873: Combined targeting of Akt and MEK with the Akt inhibitor GDC-0068 and MEK inhibitor GDC-0973 demonstrates synergistic anti-tumor effects. Cancer Research. 72(8_Supplement). 873–873. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact